Combining Survival Trials Using Aggregate Data Based on Misspecified Models

The treatment effects of the same therapy observed from multiple clinical trials can often be very different. Yet the patient characteristics accounting for these differences may not be identifiable in real world practice. There needs to be an unbiased way to combine the results from multiple trials and report the overall treatment effect for the general population during the development and validation of a new therapy. The non-linear structure of the maximum partial likelihood estimates for the (log) hazard ratio defined with a Cox proportional hazard model leads to challenges in the statistical analyses for combining such clinical trials. In this paper, we formulated the expected overall treatment effects using various modeling assumptions. Thus we are proposing efficient estimates and a version of Wald test for the combined hazard ratio using only aggregate data. Interpretation of the methods are provided in the framework of robust data analyses involving misspecified models.

[1]  Meijuan Li.  Statistical Consideration and Challenges in Bridging Study of Personalized Medicine , 2015, Journal of biopharmaceutical statistics.

[2]  J. Lawless.  Statistical Models and Methods for Lifetime Data , 2002 .

[3]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[4]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[5]  D. Mehrotra,et al.  An efficient alternative to the stratified Cox model analysis , 2012, Statistics in medicine.

[6]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[7]  John D. Kalbfleisch,et al.  Misspecified proportional hazard models , 1986 .

[8]  J. Hanley.  The Breslow estimator of the nonparametric baseline survivor function in Cox's regression model: some heuristics. , 2008, Epidemiology.

[9]  Daniel J Sargent,et al.  Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Xing Yuan,et al.  A meta-analytic framework for combining incomparable Cox proportional hazard models caused by omitting important covariates , 2009 .

[11]  R. Gill,et al.  Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .

[12]  John D. Kalbfleisch,et al.  The Statistical Analysis of Failure Data , 1986, IEEE Transactions on Reliability.

[13]  Jonathan Denne,et al.  Identifying a Subpopulation for a Tailored Therapy: Bridging Clinical Efficacy From a Laboratory-Developed Assay to a Validated In Vitro Diagnostic Test Kit , 2014 .

[14]  S. Johansen.  An Extension of Cox's Regression Model , 1983 .

[15]  J. A. Fill,et al.  Stochastic monotonicity and realizable monotonicity , 2000, math/0005267.

[16]  M. Kenward,et al.  Contribution to the discussion of the paper by Diggle, Tawn and Moyeed , 1998 .

[17]  L. J. Wei,et al.  Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .

[18]  L. J. Wei,et al.  The Robust Inference for the Cox Proportional Hazards Model , 1989 .

[19]  H. White.  Maximum Likelihood Estimation of Misspecified Models , 1982 .

[20]  Gordon Johnston,et al.  Statistical Models and Methods for Lifetime Data , 2003, Technometrics.